Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. Issue 7 (July 2019)

• Record Type: Journal Article
• Authors: Soumerai, Jacob D; Ni, Ai; Darif, Mohamed; Londhe, Anil; Xing, Guan; Mun, Yong; Kay, Neil E; Shanafelt, Tait D; Rabe, Kari G; Byrd, John C; Chanan-Khan, Asher A; Furman, Richard R; Hillmen, Peter; Jones, Jeffrey; Seymour, John F; Sharman, Jeffrey P; Ferrante, Lucille; Mobasher, Mehrdad; Stark, Thomas; Reddy, Vijay; Dreiling, Lyndah K; Bhargava, Pankaj; Howes, Angela; James, Danelle F; Zelenetz, Andrew D
• Is Part Of: Lancet. Volume 6:Issue 7(2019)
• Page Start: e366
• Page End: e374
• Publication Date: 2019-07
• Subjects: Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15005
• DOI: 10.1016/S2352-3026(19)30085-7
• Languages: English
• ISSNs: 2352-3026

Abstract

Summary: Background: Clinically validated prognostic models for overall survival do not exist for patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) who are on targeted therapies. We aimed to create a prognostic model to identify high-risk individuals who do not achieve a good outcome with available targeted therapies. Methods: In this retrospective, pooled cohort study, 2475 patients with CLL treated between June 22, 2012, and Sept 23, 2015, in six randomised trials of ibrutinib, idelalisib, and venetoclax, or at the Mayo Clinic CLL Database (MCCD) were included. Eligible patients had CLL, were previously treated, were aged 18 years or older, had ECOG performance status 0–1, and required further treatment as per the international workshop on CLL 2008 criteria. There was heterogeneity in other eligibility criteria. We evaluated 28 candidate factors known to affect the overall survival of these patients and applied univariate and multivariate analyses to derive the risk score in a training dataset (n=727) of patients treated with ibrutinib or chemoimmunotherapy. We validated the score in an internal-validation dataset (n=242) of patients treated with ibrutinib or chemoimmunotherapy and three external-validation datasets (idelalisib or chemoimmunotherapy dataset, n=897; venetoclax or chemoimmunotherapy dataset, n=389; and the MCCD [including patients treated with heterogeneous therapies], n=220), applying C-statistics as a measure of discrimination. Findings: The derived model consisted of four factors (one point each; serum β2 -microglobulin ≥5 mg/dL, lactate dehydrogenase >upper limit of normal, haemoglobin <110 g/L for women or <120 g/L for men, and time from initiation of last therapy <24 months), separating patients into low (score 0–1), intermediate (score 2–3), and high risk (score 4) groups. The risk score was prognostic for overall survival in the training dataset (CS=0·74, 95% CI 0·60–0·85, log-rank p<0·0001), and in the internal-validation (CS=0·79, 0·56–0·97, log-rank p=0·0003), and all three external-validation cohorts (idelalisib or chemoimmunotherapy: CS=0·71, 0·59–0·81, log-rank p<0·0001; venetoclax or chemoimmunotherapy: CS =0·76, 0·66–0·85, log-rank p=0·014; MCCD cohort: CS=0·61, 0·56–0·66), log-rank p<0·0001). The risk score is available onCalculate by QxMD . Interpretation: We present the first validated risk score to predict overall survival in patients with relapsed or refractory CLL treated with targeted therapy. The model is applicable to patients treated with all currently approved targeted therapies (ibrutinib, idelalisib, and venetoclax) and chemoimmunotherapy. This tool allows the identification of a well defined cohort of previously treated patients with CLL who are at high risk of death, and could be used in future prospective trials to test therapeutic options for these patients with an unmet clinical need. Funding: Lymphoma Research Foundation, Lymphoma Research Fund (Andrew D Zelenetz), and National Institutes of Health/National Cancer Institute.